Private Wealth Partners LLC Has $12.95 Million Position in Pfizer Inc. (NYSE:PFE)

Private Wealth Partners LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 7.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 447,537 shares of the biopharmaceutical company’s stock after acquiring an additional 31,321 shares during the quarter. Pfizer makes up about 1.0% of Private Wealth Partners LLC’s portfolio, making the stock its 28th largest holding. Private Wealth Partners LLC’s holdings in Pfizer were worth $12,952,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PFE. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $29,000. Quarry LP bought a new position in Pfizer during the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer in the first quarter valued at $37,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group increased their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.7 %

PFE opened at $28.09 on Friday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company’s 50-day moving average is $29.03 and its 200 day moving average is $28.59. The firm has a market capitalization of $159.18 billion, a P/E ratio of 37.96, a PEG ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The company’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.98%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.